Pioneering biased ligand offers efficacy with reduced on-target toxicity

Nat Rev Drug Discov. 2015 Dec;14(12):809-10. doi: 10.1038/nrd4784.
No abstract available

MeSH terms

  • Analgesics, Opioid / pharmacology
  • Clinical Trials, Phase II as Topic
  • Drug Discovery
  • Drug-Related Side Effects and Adverse Reactions* / metabolism
  • Drug-Related Side Effects and Adverse Reactions* / prevention & control
  • Humans
  • Ligands
  • Receptors, Opioid, mu / physiology*
  • Signal Transduction
  • Spiro Compounds / pharmacology*
  • Thiophenes / pharmacology*

Substances

  • ((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
  • Analgesics, Opioid
  • Ligands
  • Receptors, Opioid, mu
  • Spiro Compounds
  • Thiophenes